News

Events

Keep abreast of our presence at biotech and drug discovery events

June 11, 2026

June 11-18, 2026, European Hematology Association (EHA) Congress

Phase 1 First-in-human study of AUR112, a highly selective MALT1 inhibitor, in relapsed lymphoid malignancies

April 17, 2026

April 17-22, 2026, American Association for Cancer Research

1) Exceptionally selective and orally bioavailable p300 degraders for the treatment of CBP-mutant and p300-dependent cancers 2) Discovery and characterization of once...

Events